Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 78

1.

Identification of HIV transmitting CD11c+ human epidermal dendritic cells.

Bertram KM, Botting RA, Baharlou H, Rhodes JW, Rana H, Graham JD, Patrick E, Fletcher J, Plasto TM, Truong NR, Royle C, Doyle CM, Tong O, Nasr N, Barnouti L, Kohout MP, Brooks AJ, Wines MP, Haertsch P, Lim J, Gosselink MP, Ctercteko G, Estes JD, Churchill MJ, Cameron PU, Hunter E, Haniffa MA, Cunningham AL, Harman AN.

Nat Commun. 2019 Jun 21;10(1):2759. doi: 10.1038/s41467-019-10697-w.

2.

Glatiramer Acetate Reverses Motor Dysfunction and the Decrease in Tyrosine Hydroxylase Levels in a Mouse Model of Parkinson's Disease.

Churchill MJ, Cantu MA, Kasanga EA, Moore C, Salvatore MF, Meshul CK.

Neuroscience. 2019 Jun 18;414:8-27. doi: 10.1016/j.neuroscience.2019.06.006. [Epub ahead of print]

PMID:
31220543
3.

Quantifying Leukocyte Egress via Lymphatic Vessels from Murine Skin and Tumors.

Steele MM, Churchill MJ, Breazeale AP, Lane RS, Nelson NA, Lund AW.

J Vis Exp. 2019 Jan 7;(143). doi: 10.3791/58704.

PMID:
30663703
4.

HIV latency can be established in proliferating and nonproliferating resting CD4+ T cells in vitro: implications for latency reversal.

Moso MA, Anderson JL, Adikari S, Gray LR, Khoury G, Chang JJ, Jacobson JC, Ellett AM, Cheng WJ, Saleh S, Zaunders JJ, Purcell DFJ, Cameron PU, Churchill MJ, Lewin SR, Lu HK.

AIDS. 2019 Feb 1;33(2):199-209. doi: 10.1097/QAD.0000000000002075.

PMID:
30562171
5.

Dietary therapy restores glutamatergic input to orexin/hypocretin neurons after traumatic brain injury in mice.

Elliott JE, De Luche SE, Churchill MJ, Moore C, Cohen AS, Meshul CK, Lim MM.

Sleep. 2018 Mar 1;41(3). doi: 10.1093/sleep/zsx212.

6.

Bone Marrow Myeloid Cells Regulate Myeloid-Biased Hematopoietic Stem Cells via a Histamine-Dependent Feedback Loop.

Chen X, Deng H, Churchill MJ, Luchsinger LL, Du X, Chu TH, Friedman RA, Middelhoff M, Ding H, Tailor YH, Wang ALE, Liu H, Niu Z, Wang H, Jiang Z, Renders S, Ho SH, Shah SV, Tishchenko P, Chang W, Swayne TC, Munteanu L, Califano A, Takahashi R, Nagar KK, Renz BW, Worthley DL, Westphalen CB, Hayakawa Y, Asfaha S, Borot F, Lin CS, Snoeck HW, Mukherjee S, Wang TC.

Cell Stem Cell. 2017 Dec 7;21(6):747-760.e7. doi: 10.1016/j.stem.2017.11.003. Epub 2017 Nov 30.

7.

Exercise in an animal model of Parkinson's disease: Motor recovery but not restoration of the nigrostriatal pathway.

Churchill MJ, Pflibsen L, Sconce MD, Moore C, Kim K, Meshul CK.

Neuroscience. 2017 Sep 17;359:224-247. doi: 10.1016/j.neuroscience.2017.07.031. Epub 2017 Jul 25.

PMID:
28754312
8.

Histidine decarboxylase (HDC)-expressing granulocytic myeloid cells induce and recruit Foxp3+ regulatory T cells in murine colon cancer.

Chen X, Takemoto Y, Deng H, Middelhoff M, Friedman RA, Chu TH, Churchill MJ, Ma Y, Nagar KK, Tailor YH, Mukherjee S, Wang TC.

Oncoimmunology. 2017 Feb 10;6(3):e1290034. doi: 10.1080/2162402X.2017.1290034. eCollection 2017.

9.

Plastic changes at corticostriatal synapses predict improved motor function in a partial lesion model of Parkinson's disease.

Bentea E, Moore C, Deneyer L, Verbruggen L, Churchill MJ, Hood RL, Meshul CK, Massie A.

Brain Res Bull. 2017 Apr;130:257-267. doi: 10.1016/j.brainresbull.2017.02.005. Epub 2017 Feb 20.

PMID:
28232022
10.

Frequency and Env determinants of HIV-1 subtype C strains from antiretroviral therapy-naive subjects that display incomplete inhibition by maraviroc.

Borm K, Jakobsen MR, Cashin K, Flynn JK, Ellenberg P, Ostergaard L, Lee B, Churchill MJ, Roche M, Gorry PR.

Retrovirology. 2016 Nov 3;13(1):74.

11.

Strategies to target HIV-1 in the central nervous system.

Gray LR, Brew BJ, Churchill MJ.

Curr Opin HIV AIDS. 2016 Jul;11(4):371-5. doi: 10.1097/COH.0000000000000278. Review.

PMID:
26945147
12.

Lipidomic dataset of plasma from patients infected with wild type and nef-deficient HIV-1 strain.

Meikle P, Low H, Churchill MJ, Bukrinsky M, Sviridov D.

Data Brief. 2015 Dec 11;6:168-75. doi: 10.1016/j.dib.2015.11.067. eCollection 2016 Mar.

13.

Toxicity and in vitro activity of HIV-1 latency-reversing agents in primary CNS cells.

Gray LR, On H, Roberts E, Lu HK, Moso MA, Raison JA, Papaioannou C, Cheng WJ, Ellett AM, Jacobson JC, Purcell DF, Wesselingh SL, Gorry PR, Lewin SR, Churchill MJ.

J Neurovirol. 2016 Aug;22(4):455-63. doi: 10.1007/s13365-015-0413-4. Epub 2016 Jan 4.

PMID:
26727904
14.

Cyclosporin promotes neurorestoration and cell replacement therapy in pre-clinical models of Parkinson's disease.

Tamburrino A, Churchill MJ, Wan OW, Colino-Sanguino Y, Ippolito R, Bergstrand S, Wolf DA, Herz NJ, Sconce MD, Björklund A, Meshul CK, Decressac M.

Acta Neuropathol Commun. 2015 Dec 14;3:84. doi: 10.1186/s40478-015-0263-6.

15.

HIV reservoirs: what, where and how to target them.

Churchill MJ, Deeks SG, Margolis DM, Siliciano RF, Swanstrom R.

Nat Rev Microbiol. 2016 Jan;14(1):55-60. doi: 10.1038/nrmicro.2015.5. Epub 2015 Nov 30. Review.

PMID:
26616417
16.

Lipid metabolism in patients infected with Nef-deficient HIV-1 strain.

Low H, Cheng L, Di Yacovo MS, Churchill MJ, Meikle P, Bukrinsky M, Hill AF, Sviridov D.

Atherosclerosis. 2016 Jan;244:22-8. doi: 10.1016/j.atherosclerosis.2015.10.103. Epub 2015 Oct 30.

17.

IL-17 producing mast cells promote the expansion of myeloid-derived suppressor cells in a mouse allergy model of colorectal cancer.

Chen X, Churchill MJ, Nagar KK, Tailor YH, Chu T, Rush BS, Jiang Z, Wang EB, Renz BW, Wang H, Fung MC, Worthley DL, Mukherjee S, Wang TC.

Oncotarget. 2015 Oct 20;6(32):32966-79. doi: 10.18632/oncotarget.5435.

18.

Molecular Gymnastics: Mechanisms of HIV-1 Resistance to CCR5 Antagonists and Impact on Virus Phenotypes.

Roche M, Borm K, Flynn JK, Lewin SR, Churchill MJ, Gorry PR.

Curr Top Med Chem. 2016;16(10):1091-106. Review.

PMID:
26324043
19.

CNS-specific regulatory elements in brain-derived HIV-1 strains affect responses to latency-reversing agents with implications for cure strategies.

Gray LR, Cowley D, Welsh C, Lu HK, Brew BJ, Lewin SR, Wesselingh SL, Gorry PR, Churchill MJ.

Mol Psychiatry. 2016 Apr;21(4):574-84. doi: 10.1038/mp.2015.111. Epub 2015 Aug 25.

20.

Inhibition of catechol-O-methyl transferase (COMT) by tolcapone restores reductions in microtubule-associated protein 2 (MAP2) and synaptophysin (SYP) following exposure of neuronal cells to neurotropic HIV.

Lee TT, Chana G, Gorry PR, Ellett A, Bousman CA, Churchill MJ, Gray LR, Everall IP.

J Neurovirol. 2015 Oct;21(5):535-43. doi: 10.1007/s13365-015-0354-y. Epub 2015 Jun 3.

21.

Intervention with exercise restores motor deficits but not nigrostriatal loss in a progressive MPTP mouse model of Parkinson's disease.

Sconce MD, Churchill MJ, Greene RE, Meshul CK.

Neuroscience. 2015 Jul 23;299:156-74. doi: 10.1016/j.neuroscience.2015.04.069. Epub 2015 May 2.

PMID:
25943481
22.

MPTP-induced parkinsonism in mice alters striatal and nigral xCT expression but is unaffected by the genetic loss of xCT.

Bentea E, Sconce MD, Churchill MJ, Van Liefferinge J, Sato H, Meshul CK, Massie A.

Neurosci Lett. 2015 Apr 23;593:1-6. doi: 10.1016/j.neulet.2015.03.013. Epub 2015 Mar 10.

PMID:
25766755
23.

Reliable genotypic tropism tests for the major HIV-1 subtypes.

Cashin K, Gray LR, Harvey KL, Perez-Bercoff D, Lee GQ, Sterjovski J, Roche M, Demarest JF, Drummond F, Harrigan PR, Churchill MJ, Gorry PR.

Sci Rep. 2015 Feb 25;5:8543. doi: 10.1038/srep08543.

24.

Intervention with 7,8-dihydroxyflavone blocks further striatal terminal loss and restores motor deficits in a progressive mouse model of Parkinson's disease.

Sconce MD, Churchill MJ, Moore C, Meshul CK.

Neuroscience. 2015 Apr 2;290:454-71. doi: 10.1016/j.neuroscience.2014.12.080. Epub 2015 Feb 2.

PMID:
25655214
25.

Ex vivo response to histone deacetylase (HDAC) inhibitors of the HIV long terminal repeat (LTR) derived from HIV-infected patients on antiretroviral therapy.

Lu HK, Gray LR, Wightman F, Ellenberg P, Khoury G, Cheng WJ, Mota TM, Wesselingh S, Gorry PR, Cameron PU, Churchill MJ, Lewin SR.

PLoS One. 2014 Nov 19;9(11):e113341. doi: 10.1371/journal.pone.0113341. eCollection 2014.

26.

Differences in coreceptor specificity contribute to alternative tropism of HIV-1 subtype C for CD4(+) T-cell subsets, including stem cell memory T-cells.

Cashin K, Paukovics G, Jakobsen MR, Østergaard L, Churchill MJ, Gorry PR, Flynn JK.

Retrovirology. 2014 Nov 12;11:97. doi: 10.1186/s12977-014-0097-5.

27.
28.

Is the central nervous system a reservoir of HIV-1?

Gray LR, Roche M, Flynn JK, Wesselingh SL, Gorry PR, Churchill MJ.

Curr Opin HIV AIDS. 2014 Nov;9(6):552-8. doi: 10.1097/COH.0000000000000108. Review.

29.

HIV-1 transcriptional regulation in the central nervous system and implications for HIV cure research.

Churchill MJ, Cowley DJ, Wesselingh SL, Gorry PR, Gray LR.

J Neurovirol. 2015 Jun;21(3):290-300. doi: 10.1007/s13365-014-0271-5. Epub 2014 Jul 25. Review.

30.

HIV-1 entry and trans-infection of astrocytes involves CD81 vesicles.

Gray LR, Turville SG, Hitchen TL, Cheng WJ, Ellett AM, Salimi H, Roche MJ, Wesselingh SL, Gorry PR, Churchill MJ.

PLoS One. 2014 Feb 28;9(2):e90620. doi: 10.1371/journal.pone.0090620. eCollection 2014.

31.

Quantifying susceptibility of CD4+ stem memory T-cells to infection by laboratory adapted and clinical HIV-1 strains.

Flynn JK, Paukovics G, Cashin K, Borm K, Ellett A, Roche M, Jakobsen MR, Churchill MJ, Gorry PR.

Viruses. 2014 Feb 10;6(2):709-26. doi: 10.3390/v6020709.

32.

Presynaptic alpha-synuclein aggregation in a mouse model of Parkinson's disease.

Spinelli KJ, Taylor JK, Osterberg VR, Churchill MJ, Pollock E, Moore C, Meshul CK, Unni VK.

J Neurosci. 2014 Feb 5;34(6):2037-50. doi: 10.1523/JNEUROSCI.2581-13.2014.

33.

Loss of leucine-rich repeat kinase 2 (LRRK2) in rats leads to progressive abnormal phenotypes in peripheral organs.

Baptista MA, Dave KD, Frasier MA, Sherer TB, Greeley M, Beck MJ, Varsho JS, Parker GA, Moore C, Churchill MJ, Meshul CK, Fiske BK.

PLoS One. 2013 Nov 14;8(11):e80705. doi: 10.1371/journal.pone.0080705. eCollection 2013.

34.

Linkages between HIV-1 specificity for CCR5 or CXCR4 and in vitro usage of alternative coreceptors during progressive HIV-1 subtype C infection.

Cashin K, Jakobsen MR, Sterjovski J, Roche M, Ellett A, Flynn JK, Borm K, Gouillou M, Churchill MJ, Gorry PR.

Retrovirology. 2013 Sep 16;10:98. doi: 10.1186/1742-4690-10-98.

35.

Longitudinal Analysis of CCR5 and CXCR4 Usage in a Cohort of Antiretroviral Therapy-Naïve Subjects with Progressive HIV-1 Subtype C Infection.

Jakobsen MR, Cashin K, Roche M, Sterjovski J, Ellett A, Borm K, Flynn J, Erikstrup C, Gouillou M, Gray LR, Saksena NK, Wang B, Purcell DF, Kallestrup P, Zinyama-Gutsire R, Gomo E, Ullum H, Ostergaard L, Lee B, Ramsland PA, Churchill MJ, Gorry PR.

PLoS One. 2013 Jun 18;8(6):e65950. doi: 10.1371/journal.pone.0065950. Print 2013.

36.

The NRTIs lamivudine, stavudine and zidovudine have reduced HIV-1 inhibitory activity in astrocytes.

Gray LR, Tachedjian G, Ellett AM, Roche MJ, Cheng WJ, Guillemin GJ, Brew BJ, Turville SG, Wesselingh SL, Gorry PR, Churchill MJ.

PLoS One. 2013 Apr 16;8(4):e62196. doi: 10.1371/journal.pone.0062196. Print 2013.

37.

A common mechanism of clinical HIV-1 resistance to the CCR5 antagonist maraviroc despite divergent resistance levels and lack of common gp120 resistance mutations.

Roche M, Salimi H, Duncan R, Wilkinson BL, Chikere K, Moore MS, Webb NE, Zappi H, Sterjovski J, Flynn JK, Ellett A, Gray LR, Lee B, Jubb B, Westby M, Ramsland PA, Lewin SR, Payne RJ, Churchill MJ, Gorry PR.

Retrovirology. 2013 Apr 20;10:43. doi: 10.1186/1742-4690-10-43.

38.

The magnitude of HIV-1 resistance to the CCR5 antagonist maraviroc may impart a differential alteration in HIV-1 tropism for macrophages and T-cell subsets.

Flynn JK, Paukovics G, Moore MS, Ellett A, Gray LR, Duncan R, Salimi H, Jubb B, Westby M, Purcell DF, Lewin SR, Lee B, Churchill MJ, Gorry PR, Roche M.

Virology. 2013 Jul 20;442(1):51-8. doi: 10.1016/j.virol.2013.03.026. Epub 2013 Apr 17.

39.

CoRSeqV3-C: a novel HIV-1 subtype C specific V3 sequence based coreceptor usage prediction algorithm.

Cashin K, Gray LR, Jakobsen MR, Sterjovski J, Churchill MJ, Gorry PR.

Retrovirology. 2013 Feb 27;10:24. doi: 10.1186/1742-4690-10-24.

40.

Macrophage-tropic HIV-1 variants from brain demonstrate alterations in the way gp120 engages both CD4 and CCR5.

Salimi H, Roche M, Webb N, Gray LR, Chikere K, Sterjovski J, Ellett A, Wesselingh SL, Ramsland PA, Lee B, Churchill MJ, Gorry PR.

J Leukoc Biol. 2013 Jan;93(1):113-26. doi: 10.1189/jlb.0612308. Epub 2012 Oct 17.

41.

Reduced basal transcriptional activity of central nervous system-derived HIV type 1 long terminal repeats.

Gray LR, Cowley D, Crespan E, Welsh C, Mackenzie C, Wesselingh SL, Gorry PR, Churchill MJ.

AIDS Res Hum Retroviruses. 2013 Feb;29(2):365-70. doi: 10.1089/AID.2012.0138. Epub 2012 Sep 25.

42.

Structural elements of primary CCR5-using HIV-1 gp120 proteins influencing sensitivity and resistance to the broadly neutralizing monoclonal antibody b12.

Sterjovski J, Churchill MJ, Ellett A, Wesselingh SL, Ramsland PA, Gorry PR.

Virology. 2012 Oct 25;432(2):394-404. doi: 10.1016/j.virol.2012.06.024. Epub 2012 Jul 19.

43.

HIV-1 predisposed to acquiring resistance to maraviroc (MVC) and other CCR5 antagonists in vitro has an inherent, low-level ability to utilize MVC-bound CCR5 for entry.

Roche M, Jakobsen MR, Ellett A, Salimiseyedabad H, Jubb B, Westby M, Lee B, Lewin SR, Churchill MJ, Gorry PR.

Retrovirology. 2011 Nov 7;8:89. doi: 10.1186/1742-4690-8-89.

44.

Alternative coreceptor requirements for efficient CCR5- and CXCR4-mediated HIV-1 entry into macrophages.

Cashin K, Roche M, Sterjovski J, Ellett A, Gray LR, Cunningham AL, Ramsland PA, Churchill MJ, Gorry PR.

J Virol. 2011 Oct;85(20):10699-709. doi: 10.1128/JVI.05510-11. Epub 2011 Aug 10.

45.

Increased sensitivity to broadly neutralizing antibodies of end-stage disease R5 HIV-1 correlates with evolution in Env glycosylation and charge.

Borggren M, Repits J, Sterjovski J, Uchtenhagen H, Churchill MJ, Karlsson A, Albert J, Achour A, Gorry PR, Fenyö EM, Jansson M.

PLoS One. 2011;6(6):e20135. doi: 10.1371/journal.pone.0020135. Epub 2011 Jun 16.

46.
47.

HIV-1 escape from the CCR5 antagonist maraviroc associated with an altered and less-efficient mechanism of gp120-CCR5 engagement that attenuates macrophage tropism.

Roche M, Jakobsen MR, Sterjovski J, Ellett A, Posta F, Lee B, Jubb B, Westby M, Lewin SR, Ramsland PA, Churchill MJ, Gorry PR.

J Virol. 2011 May;85(9):4330-42. doi: 10.1128/JVI.00106-11. Epub 2011 Feb 23.

48.

CD4-binding site alterations in CCR5-using HIV-1 envelopes influencing gp120-CD4 interactions and fusogenicity.

Sterjovski J, Churchill MJ, Roche M, Ellett A, Farrugia W, Wesselingh SL, Cunningham AL, Ramsland PA, Gorry PR.

Virology. 2011 Feb 20;410(2):418-28. doi: 10.1016/j.virol.2010.12.010. Epub 2011 Jan 8.

49.

CD4 and MHC class 1 down-modulation activities of nef alleles from brain- and lymphoid tissue-derived primary HIV-1 isolates.

Gray LR, Gabuzda D, Cowley D, Ellett A, Chiavaroli L, Wesselingh SL, Churchill MJ, Gorry PR.

J Neurovirol. 2011 Feb;17(1):82-91. doi: 10.1007/s13365-010-0001-6. Epub 2010 Nov 30.

50.

Genetic and functional heterogeneity of CNS-derived tat alleles from patients with HIV-associated dementia.

Cowley D, Gray LR, Wesselingh SL, Gorry PR, Churchill MJ.

J Neurovirol. 2011 Feb;17(1):70-81. doi: 10.1007/s13365-010-0002-5. Epub 2010 Nov 30.

PMID:
21165788

Supplemental Content

Loading ...
Support Center